[go: up one dir, main page]

RU94028109A - NEW SUBSTITUTED SALICYL ACIDS, METHOD OF THEIR RECEIVING - Google Patents

NEW SUBSTITUTED SALICYL ACIDS, METHOD OF THEIR RECEIVING

Info

Publication number
RU94028109A
RU94028109A RU94028109/04A RU94028109A RU94028109A RU 94028109 A RU94028109 A RU 94028109A RU 94028109/04 A RU94028109/04 A RU 94028109/04A RU 94028109 A RU94028109 A RU 94028109A RU 94028109 A RU94028109 A RU 94028109A
Authority
RU
Russia
Prior art keywords
substance
receiving
new substituted
acids
group
Prior art date
Application number
RU94028109/04A
Other languages
Russian (ru)
Other versions
RU2124501C1 (en
Inventor
Хуберт Агбак Карл
Ахргрен Лейф
Берглинд Томас
Харальдссон Мартин
Ольссон Ларс-Инге
Смедегорд Геран
Original Assignee
Каби Фармациа АБ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9103397A external-priority patent/SE9103397D0/en
Application filed by Каби Фармациа АБ filed Critical Каби Фармациа АБ
Publication of RU94028109A publication Critical patent/RU94028109A/en
Application granted granted Critical
Publication of RU2124501C1 publication Critical patent/RU2124501C1/en

Links

Claims (1)

Описано вещество формулы Гет-NR-SO2-Ph1-A-Ph2(COOH)(OH) и таутомерные формы, соли и сольваты, сложные алкиловые эфиры с 1-6 атомами углерода и фармацевтические композиции вещества. Ph1 и Ph2 представляют собой бензольные кольца при условии, что карбокси- и гидрокси- группы находятся в орто-положении друг к другу. Гет включает необязательно замещенное гетероциклическое кольцо, которое включает сопряженные двойные связи и присоединено к атому азота в группе NR. Это вещество отличается тем, что А является мостиком, который является стабильным против восстановления, поскольку он не является азогруппой, и тем что R является атомом водорода или низшим алкилом. Изобретение также включает способ получения этого вещества и его использование в качестве медикамента, в частности для лечения аутоиммунных заболеваний.A substance of the formula Get-NR-SO 2 -Ph 1 -A-Ph 2 (COOH) (OH) and tautomeric forms, salts and solvates, alkyl esters with 1-6 carbon atoms and pharmaceutical compositions of the substance are described. Ph 1 and Ph 2 are benzene rings, provided that the carboxy and hydroxy groups are ortho to each other. A geth includes an optionally substituted heterocyclic ring that includes conjugated double bonds and is attached to a nitrogen atom in the NR group. This substance differs in that A is a bridge that is stable against reduction because it is not an azo group, and in that R is a hydrogen atom or lower alkyl. The invention also includes a method of obtaining this substance and its use as a drug, in particular for the treatment of autoimmune diseases.
RU94028109A 1991-11-18 1992-11-04 Salicylic acid derivatives, alkyl esters thereof containing from 1 to 6 carbon atoms in ester group, salts and solvates RU2124501C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (en) 1991-11-18 1991-11-18 NEW SUBSTITUTED SALICYL ACIDS
SE9103397-7 1991-11-18

Publications (2)

Publication Number Publication Date
RU94028109A true RU94028109A (en) 1996-01-10
RU2124501C1 RU2124501C1 (en) 1999-01-10

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94028109A RU2124501C1 (en) 1991-11-18 1992-11-04 Salicylic acid derivatives, alkyl esters thereof containing from 1 to 6 carbon atoms in ester group, salts and solvates

Country Status (29)

Country Link
US (3) US5302718A (en)
EP (1) EP0613468B1 (en)
JP (1) JP3259915B2 (en)
KR (1) KR100253748B1 (en)
AT (1) ATE194597T1 (en)
AU (1) AU668528B2 (en)
CA (1) CA2123697C (en)
DE (1) DE69231252T2 (en)
DK (1) DK0613468T3 (en)
EE (1) EE03026B1 (en)
ES (1) ES2149780T3 (en)
FI (1) FI106857B (en)
GR (1) GR3034585T3 (en)
HU (2) HU221476B (en)
IL (1) IL103665A (en)
LT (1) LT3182B (en)
LV (1) LV10246B (en)
MX (1) MX9206647A (en)
MY (1) MY130169A (en)
NO (1) NO300805B1 (en)
NZ (1) NZ244998A (en)
PT (1) PT101068B (en)
RU (1) RU2124501C1 (en)
SE (1) SE9103397D0 (en)
SK (1) SK282080B6 (en)
TW (1) TW304944B (en)
UA (1) UA42869C2 (en)
WO (1) WO1993010094A1 (en)
ZA (1) ZA928864B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
JPH09124620A (en) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co Substituted biphenylsulfonamide endothelin antagonist
SG87052A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Pinacol ester intermediates useful for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (en) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 4-fluorosalicylic acids
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
JP2003520758A (en) 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド Treatment of anti-estrogen resistant breast cancer with RXR modulator
JP2002540088A (en) 1999-03-19 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー Method for producing biphenyl isoxazole / sulfonamide compound
AU6853700A (en) 1999-09-04 2001-04-10 Astrazeneca Ab Chemical compounds
WO2001017942A1 (en) 1999-09-04 2001-03-15 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
DE60009319T2 (en) 1999-09-04 2005-03-31 Astrazeneca Ab SUBSTITUTED N-PHENYL-2-HYDROXY-2-METHYL-3,3,3-TRIFLUORPROPANAMID DERIVATIVES FOR INCREASING PYRUVATE DEHYDROGENASE ACTIVITY
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
DE60115414D1 (en) * 2000-04-28 2006-01-05 Univ British Columbia N-HETEROSUBSTITUTED SALICYLATES FOR THE TREATMENT OF CANCER
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
WO2005023771A1 (en) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
EP1696915A1 (en) * 2003-12-19 2006-09-06 Pfizer, Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
MXPA06014023A (en) * 2004-06-29 2007-02-08 Warner Lambert Co Combination therapies utilizing benzamide inhibitors of the p2x7 receptor.
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
MX2008010668A (en) * 2006-02-21 2008-10-01 Amgen Inc Cinnoline derivatives as phosphodiesterase 10 inhibitors.
EP2305641A4 (en) * 2008-06-23 2012-08-22 Astellas Pharma Inc Sulfonamide compound or salt thereof
EP2677865A4 (en) * 2011-02-23 2015-04-22 Icahn School Med Mount Sinai Inhibitors of bromodomains as modulators of gene expression
WO2016187308A1 (en) 2015-05-20 2016-11-24 Amgen Inc. Triazole agonists of the apj receptor
CN108602775B (en) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 Mast cell regulators and uses thereof
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (en) * 2019-12-13 2021-01-19 西安交通大学 Sulfonamide compound and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (en) * 1971-11-26 1973-05-24 Pharmacia Ab NEW DERIVATIVES OF PYRIDINE
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Similar Documents

Publication Publication Date Title
RU94028109A (en) NEW SUBSTITUTED SALICYL ACIDS, METHOD OF THEIR RECEIVING
SE9103397D0 (en) NEW SUBSTITUTED SALICYL ACIDS
ES2158537T3 (en) DERIVATIVES OF CYCLOPROPILALCANOIC ACIDS.
NO304186B1 (en) 1H-indole-3-glycosylamide and pharmaceutical formulation
ES538418A0 (en) A DERIVATIVE OF INDOL-3-CARBOXAMIDE
FI940414A0 (en) Quinoline or quinazoline derivatives, their preparation and use
EA199801028A1 (en) APPLICATION OF DERIVATIVES OF P-AMINOPHENOL FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
ES8707245A1 (en) Antibacterial compounds.
HUP9700810A2 (en) Acids and esters of diosmetin and pharmaceutical compositions containing them
KR970703301A (en) Novel Diaminomethylidene Derivatives (NOVEL DIAMINCMETHYLIDENE DERIVATIVE)
DK0628042T3 (en) Serotoninergic ergoline derivatives
GR880100526A (en) Pharmaceutical products for local treatment
KR970701542A (en) OCULAR TENSION DEPRESSANT
GB1505525A (en) Pyridopyrimidines
KR930007932A (en) Use of substituted tetrahydrothiophene as a medicament, novel active substance and preparation method thereof
NZ222593A (en) Cephalosporin derivatives and pharmaceutical compositions
RU93005141A (en) NEW METHODREXAT DERIVATIVES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATION ON THEIR BASIS